international journal of health policy and management سال:2016 - دوره:5

Fa | Ar | En


international journal of health policy and management
سال:2016 - دوره:5 - شماره:5

achieving universal health coverage by focusing on primary care in japan: lessons for low- and middle-income countries - صفحه:291-293 an implementation research approach to evaluating health insurance programs: insights from india - صفحه:295-299 correspondence: towards a global social support system: a response to the recent commentaries - صفحه:345-346 health rights and realization; comment on “rights language in the sustainable development agenda: has right to health discourse and norms shaped health goals?” - صفحه:341-344 improving injectable medicines prescription in outpatient services: a path towards rational use of medicines in iran - صفحه:321-324 in search of the third eye, when the two others are shamefacedly shut?; comment on “are sexual and reproductive health policies designed for all? vulnerable groups in policy documents of four european countries and their involvement in policy development” - صفحه:325-327 inequalities in health status from eq-5d findings: a cross-sectional study in low-income communities of bangladesh - صفحه:301-308 power and politics in the global health landscape: beliefs, competition and negotiation among global advocacy coalitions in the policy-making process - صفحه:309-320 searching for the right to health in the sustainable development agenda; comment on “rights language in the sustainable development agenda: has right to health discourse and norms shaped health goals?” - صفحه:337-339 the tip of the iceberg of misleading online advertising; comment on “trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of fda warning letters” - صفحه:329-331 trouble spots in online direct-to-consumer prescription drug promotion: teaching drug marketers how to inform better or spin better?; comment on “trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of fda warning letters” - صفحه:333-335